The global spatial genomics and transcriptomics market size is accounted at USD 323.53 million in 2025 and is forecasted to hit around USD 911.71 million by 2034, representing a CAGR of 12.20% from 2025 to 2034. The North America market size was estimated at USD 126.87 million in 2024 and is expanding at a CAGR of 12.32% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Million), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Spatial Genomics and Transcriptomics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Spatial Genomics and Transcriptomics Market, by Product
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast
8.1.3. Software
8.1.3.1. Market Revenue and Forecast
9.1. Spatial Genomics and Transcriptomics Market, by Technology
9.1.1. Spatial Transcriptomics
9.1.1.1. Market Revenue and Forecast
9.1.2. Sequencing-Based Methods
9.1.2.1. Market Revenue and Forecast
9.1.3. IHC
9.1.3.1. Market Revenue and Forecast
9.1.4. Microscopy-Based RNA Imaging Techniques
9.1.4.1. Market Revenue and Forecast
9.1.5. Spatial Genomics
9.1.5.1. Market Revenue and Forecast
10.1. Spatial Genomics and Transcriptomics Market, by End-use
10.1.1. Translational Research
10.1.1.1. Market Revenue and Forecast
10.1.2. Academic Customers
10.1.2.1. Market Revenue and Forecast
10.1.3. Diagnostic Customers
10.1.3.1. Market Revenue and Forecast
10.1.4. Pharmaceutical Manufacturer
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Technology
11.1.3. Market Revenue and Forecast, by End-use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Technology
11.1.4.3. Market Revenue and Forecast, by End-use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Technology
11.1.5.3. Market Revenue and Forecast, by End-use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Technology
11.2.3. Market Revenue and Forecast, by End-use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Technology
11.2.4.3. Market Revenue and Forecast, by End-use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Technology
11.2.5.3. Market Revenue and Forecast, by End-use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Technology
11.2.6.3. Market Revenue and Forecast, by End-use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Technology
11.2.7.3. Market Revenue and Forecast, by End-use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Technology
11.3.3. Market Revenue and Forecast, by End-use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Technology
11.3.4.3. Market Revenue and Forecast, by End-use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Technology
11.3.5.3. Market Revenue and Forecast, by End-use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Technology
11.3.6.3. Market Revenue and Forecast, by End-use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Technology
11.3.7.3. Market Revenue and Forecast, by End-use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Technology
11.4.3. Market Revenue and Forecast, by End-use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Technology
11.4.4.3. Market Revenue and Forecast, by End-use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Technology
11.4.5.3. Market Revenue and Forecast, by End-use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Technology
11.4.6.3. Market Revenue and Forecast, by End-use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Technology
11.4.7.3. Market Revenue and Forecast, by End-use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Technology
11.5.3. Market Revenue and Forecast, by End-use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Technology
11.5.4.3. Market Revenue and Forecast, by End-use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Technology
11.5.5.3. Market Revenue and Forecast, by End-use
12.1. Vizgen Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bruker
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bio-Techne
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Agilent Technologies, Inc.,
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Seven Bridges Genomics
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Thermo Fisher Scientific Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. 10x Genomics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Illumina, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AcelaBio
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. S2 Genomics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample